Compounds > fluoxetine

fluoxetine and ribavirin

fluoxetine has been researched along with ribavirin in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's9 (69.23)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Brunette, MF; Iber, M; Luckoor, R; Mistler, LA; Rosenberg, SD; Vidaver, RM1
Donnini, D; Franceschi, L; Furlanut, M; Sechi, L; Soardo, G1
Bai, CH; Chong, LW; Lai, HW; Liao, CS; Lin, YM; Pu, CY; Su, HC; Tsai, PJ; Tsai, YS; Tsao, CW; Young, KC1
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB1

Reviews

1 review(s) available for fluoxetine and ribavirin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

12 other study(ies) available for fluoxetine and ribavirin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
    International journal of psychiatry in medicine, 2006, Volume: 36, Issue:4

    Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antiviral Agents; Bipolar Disorder; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Fluoxetine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamotrigine; Male; Middle Aged; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triazines; Viral Load

2006
Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.
    Clinical pharmacokinetics, 2010, Volume: 49, Issue:11

    Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2010
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.
    Antiviral research, 2014, Volume: 110

    Topics: Alanine Transaminase; Antiviral Agents; Cell Line; Cell Survival; Cohort Studies; Drug Therapy, Combination; Enzyme Activation; Fluoxetine; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; JNK Mitogen-Activated Protein Kinases; Microbial Sensitivity Tests; Polyethylene Glycols; PPAR gamma; PPAR-beta; Reactive Oxygen Species; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; STAT1 Transcription Factor

2014
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:11

    Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabetes Mellitus, Type 1; Drug Repositioning; Enterovirus B, Human; Fluoxetine; Guanidine; Humans; Immunoglobulin G; Lovastatin; Oxadiazoles; Oxazoles; Oximes; Pyrazines; Ribavirin; Sulfonamides

2020